Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

• Published in: Scientific reports Vol. 13; no. 1; pp. 12869 - 14
• Main Authors: Orrù, Sandra, Pascariello, Emanuele, Pes, Barbara, Rallo, Vincenzo, Barbara, Raffaele, Muntoni, Marta, Notari, Francesca, Fancello, Gianfranco, Mocci, Cristina, Muroni, Maria Rosaria, Cossu-Rocca, Paolo, Angius, Andrea, De Miglio, Maria Rosaria
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.08.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 692/53; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer therapies; Chemotherapy; Decision making; ErbB-2 protein; Female; Gene expression; Humanities and Social Sciences; Humans; Lymph nodes; Lymphatic system; Lymphocytes, Tumor-Infiltrating; Medical prognosis; Metastases; Microenvironments; Monoclonal antibodies; multidisciplinary; Neoadjuvant Therapy; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Science; Science (multidisciplinary); Trastuzumab; Trastuzumab - therapeutic use; Treatment Outcome; Tumor Microenvironment
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-40071-2

HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant chemotherapy (NACT). The tumoral pathological complete response (pCR) rate was 40.9%. High tumoral pCR show a scarce mortality rate vs subjects with a lower response. 93.7% of ypT0 were HER2 IHC3+ BC, 6.3% were HER2 IHC 2+/SISH+ and 86.7% of ypN0 were HER2 IHC3+, the remaining were HER2 IHC2+/SISH+. Better pCR rate correlate with a high percentage of infiltrating immune cells and right-sided tumors, that reduce distant metastasis and improve survival, but no incidence difference. HER2 IHC score and laterality emerge as strong predictors of tumoral pCR after NACT from machine learning analysis. HER2 IHC3+ and G3 are poor prognostic factors for HER2+ BC patients, and could be considered in the application of neoadjuvant therapy. Increasing TILs concentrations, lower lymph node ratio and lower residual tumor cellularity are associated with a better outcome. The immune microenvironment and scarce lymph node involvement have crucial role in clinical outcomes. The combination of all predictors might offer new options for NACT effectiveness prediction and stratification of HER2+ BC during clinical decision-making.